肺炎球菌结合疫苗的研究现状及前景  

Research status and prospect of pneumococcal conjugate vaccine

作　　者：汪洋 向左云 任江伟 李珏希 黄镇 WANG Yang;XIANG Zuo-yun;REN Jiang-wei;LI Jue-xi;HUANG Zhen(WALVAX Biotechnology Co.,Ltd.,Yuxi 653100,Yunnan Province,China)

机构地区：[1]玉溪沃森生物技术有限公司,云南玉溪653100

出　　处：《中国生物制品学杂志》2022年第9期1025-1033,共9页Chinese Journal of Biologicals

基　　金：云南省重大科技专项(2015ZJ005);云南省科技成果转化项目(2019ZF007)。

摘　　要：肺炎球菌结合疫苗(pneumococcal conjugate vaccine,PCV)是当前世界范围内普遍采用的预防儿童肺炎球菌感染及该细菌引发的相关疾病的主要手段。很长一段时间PCV被国外企业垄断,近年来国产PCV成功研发并上市,极大程度缓解了我国PCV短缺问题,同时也有效减轻了肺炎球菌性疾病导致的医疗负担。但PCV采用的结合方式限制了此类疫苗的产能,同时肺炎球菌血清型的多样性也使PCV不能完全消除肺炎球菌感染威胁。本文对PCV的研究现状作一综述,以期为新型PCV的研发提供参考。Pneumococcal conjugate vaccine(PCV)is the main method to prevent pneumococcal infection and related diseases in infants and young children in the world. For a long time,PCVs have been monopolized by foreign enterprises. In recent years,domestic PCVs have been successfully developed and put onto the market,which has greatly alleviated the shortage of PCVs in China and effectively reduced the medical burden caused by pneumococcal diseases. However,the binding method used by PCVs limits the production capacity of such vaccines,and the diversity of pneumococcal serotypes also prevents PCVs from completely eliminating the threat of pneumococcal infection. This paper summarizes the research status of PCV so as to provide a reference for development of new PCVs.

关 键 词：肺炎球菌结合疫苗 肺炎球菌性疾病 流行病学 

分 类 号：R-1[医药卫生] R378.12